Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Shares Outstanding: 2023-2025

Historic Shares Outstanding for Contineum Therapeutics (CTNM) over the last 3 years, with Sep 2025 value amounting to $29.2 million.

  • Contineum Therapeutics' Shares Outstanding rose 13.39% to $29.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.2 million, marking a year-over-year increase of 13.39%. This contributed to the annual value of $25.9 million for FY2024, which is 62.54% up from last year.
  • As of Q3 2025, Contineum Therapeutics' Shares Outstanding stood at $29.2 million, which was up 12.59% from $25.9 million recorded in Q2 2025.
  • Contineum Therapeutics' 5-year Shares Outstanding high stood at $29.2 million for Q3 2025, and its period low was $11.9 million during Q1 2023.
  • Its 3-year average for Shares Outstanding is $21.2 million, with a median of $25.7 million in 2024.
  • Data for Contineum Therapeutics' Shares Outstanding shows a peak YoY skyrocketed of 68.98% (in 2024) over the last 5 years.
  • Over the past 3 years, Contineum Therapeutics' Shares Outstanding (Quarterly) stood at $15.9 million in 2023, then soared by 62.54% to $25.9 million in 2024, then climbed by 13.39% to $29.2 million in 2025.
  • Its last three reported values are $29.2 million in Q3 2025, $25.9 million for Q2 2025, and $25.9 million during Q1 2025.